CAS 654671-78-0

Sitagliptin phosphate

Description:

Sitagliptin phosphate is a pharmaceutical compound primarily used in the management of type 2 diabetes mellitus. It functions as a dipeptidyl peptidase-4 (DPP-4) inhibitor, which helps to increase insulin secretion and decrease glucagon levels in the bloodstream, thereby improving glycemic control. The substance is typically administered orally and is often prescribed in combination with other antidiabetic medications. Sitagliptin phosphate is characterized by its relatively high solubility in water, which facilitates its absorption in the gastrointestinal tract. The compound has a specific molecular structure that includes a pyrrolidine ring and a phosphate group, contributing to its biological activity. It is generally well-tolerated, with a side effect profile that may include gastrointestinal disturbances and potential risk of pancreatitis. As with any medication, it is important for patients to consult healthcare professionals for personalized advice and monitoring while using sitagliptin phosphate.

Formula: C₁₆H₁₅F₆N₅O·H₃O₄P

InChI: InChI=1S/C16H15F6N5O.H3O4P/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4/h4,6,9H,1-3,5,7,23H2;(H3,1,2,3,4)/t9-;/m1./s1

InChI key: InChIKey=IQFYVLUXQXSJJN-SBSPUUFOSA-N

SMILES: C(F)(F)(F)C=1N2C(CN(C(C[C@@H](CC3=C(F)C=C(F)C(F)=C3)N)=O)CC2)=NN1.P(=O)(O)(O)O

Synonyms:

• (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate
• 1,2,4-Triazolo[4,3-a]pyrazine, 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, phosphate (1:1)
• 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1)
• 7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate
• Glactiv
• Januvia
• Mk 0431
• Mk 431
• Sitagliptin Phosphate Intermediates
• Sitagliptin phosphate

(2R)​-​4-​Oxo-​4-​[3-​(trifluoromethyl)​-​5,​6-​dihydro-​[1,​2,​4]​triazolo[4,​3-​a]​pyrazin-​7(8H)​-​yl]​-​1-​(2,​4,​5-​trifluorophenyl)​butan-​2-​amine dihydrogen phosphate

CAS: 654671-78-0

Formula: C₁₆H₁₈F₆N₅O₅P

Purity: 98%

Color and Shape: Solid

Molecular weight: 505.3088

Ref: IN-DA003U9W

Sitagliptin Phosphate

CAS: 654671-78-0

Formula: C₁₆H₁₅F₆N₅O·H₃O₄P

Color and Shape: White To Off-White Solid

Molecular weight: 407.32 97.99

Ref: 4Z-S-206

Sitagliptin phosphate

CAS: 654671-78-0

Sitagliptin phosphate

Purity: 98%

Molecular weight: 505.31g/mol

Ref: 54-PC109238

Sitagliptin phosphate

CAS: 654671-78-0

Sitagliptin phosphate

Purity: ≥98%

Molecular weight: 505.31g/mol

Ref: 54-BUP16033

Sitagliptin Phosphate

CAS: 654671-78-0

Formula: C₁₆H₁₅F₆N₅O·H₃PO₄

Purity: >98.0%(T)(HPLC)

Color and Shape: White to Light yellow powder to crystal

Molecular weight: 505.31

Ref: 3B-I1231

Sitagliptin phosphate

CAS: 654671-78-0

Sitagliptin phosphate (MK-0431 phosphate) is a dipeptidyl peptidase-4 (DPP4) inhibitor.

Formula: C₁₆H₁₈F₆N₅O₅P

Purity: 99.72% - 99.91%

Color and Shape: White Solid

Molecular weight: 505.31

Ref: TM-T23358

Sitagliptin Phosphate

Controlled Product

CAS: 654671-78-0

Applications Sitagliptin is a trizolopyrazine dipeptidyl peptidase IV inhibitor. Sitagliptin has recently been approved for the therapy of type II diabetes.
References Kim, D., et al.: J. Med. Chem. 48, 141 (2005), Ahren, B., et al.: Eur. J. Pharmacol. 521 164 (2005), Bergman, A., et al: Clin. Ther. 28, 55 (2006)

Formula: C₁₆H₁₅F₆N₅O·H₃O₄P

Color and Shape: Neat

Molecular weight: 505.31

Ref: TR-S491000

Sitagliptin Phosphate

CAS: 654671-78-0

Formula: C₁₆H₁₅F₆N₅OH₃PO₄

Molecular weight: 407.3 : 98.0

Ref: ST-EA-CP-S3041

(R)-3-Amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4 ,3-α]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one phosphate anhydrous

CAS: 654671-78-0

(R)-3-Amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4 ,3-α]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one phosphate anhydrous (TZP) is a drug candidate for the treatment of diabetes. TZP is a prodrug that is metabolized by the liver and gut to the active compound sitagliptin phosphate (SGP). TZP has been shown to reduce plasma glucose levels in diabetic rats. In vitro experiments have shown that TZP inhibits dipeptidyl peptidase IV (DPP-IV), which is an enzyme that degrades incretins such as glucagon like peptide 1 and glucose dependent insulinotropic polypeptide. These findings suggest that TZ

Formula: C₁₆H₁₅F₆N₅O•H₃O₄P

Purity: Min. 98 Area-%

Color and Shape: Powder

Molecular weight: 505.31 g/mol

Ref: 3D-FA10819